Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270230 | 0.90 | TSHR (0.40) | TSHRSMN1; SMN2 | |
| SCHEMBL4283686 | 0.87 | TSHR (0.50) | TSHRSMN1; SMN2TDP1CYP3A4FDPS | |
| SCHEMBL4268912 | 0.87 | TSHR (0.50) | TSHRSMN1; SMN2TDP1CYP3A4FDPS | |
| SCHEMBL4269669 | 0.87 | TSHR (0.50) | TSHRSMN1; SMN2TDP1CYP3A4FDPS | |
| SCHEMBL4279894 | 0.86 | TSHR (0.42) | TSHRSMN1; SMN2 | |
| SCHEMBL4281282 | 0.85 | TSHR (0.42) | TSHRSMN1; SMN2FDPS | |
| SCHEMBL4274455 | 0.85 | TSHR (0.42) | TSHRSMN1; SMN2FDPS | |
| SCHEMBL4271923 | 0.85 | TSHR (0.42) | TSHRSMN1; SMN2FDPS | |
| SCHEMBL2783936 | 0.83 | TSHR (0.40) | TSHRSMN1; SMN2 | |
| SCHEMBL4276976 | 0.83 | LMNA (0.42) | TSHRSMN1; SMN2FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10230023-B2 | Color converter | BASF SE (DE) | 2019-03-12 | — | — | US | disclosed |
| EP-2718395-B1 | Novel illumination device comprising a colour converter | BASF SE (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-20160284947-A1 | NOVEL COLOR CONVERTER | BASF SE (DE) | 2016-09-29 | — | — | US | disclosed |
| US-9406848-B2 | Color converter | BASF SE (DE) | 2016-08-02 | — | — | US | disclosed |
| EP-2718395-A1 | NOVEL COLOR CONVERTER | BASF SE (DE) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012168395-A1 | NOVEL COLOR CONVERTER | BASF SE (DE) | 2012-12-13 | — | — | WO | disclosed |
| WO-2009037283-A1 | METHOD FOR PRODUCING SUBSTRATES COATED WITH RYLENE TETRACARBOLIC ACID DIIMIDES | BASF SE (DE) | 2009-03-26 | — | — | WO | disclosed |
| US-20090078312-A1 | VERFAHREN ZUR HERSTELLUNG VON MIT RYLENTETRACARBONSAEUREDIIMIDEN BESCHICHTETEN SUBSTRATEN | BASF SE (DE) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090078312-A1 | VERFAHREN ZUR HERSTELLUNG VON MIT RYLENTETRACARBONSAEUREDIIMIDEN BESCHICHTETEN SUBSTRATEN | AXIN2, NCSTN, NES | TSHR 3585/4885SMN1; SMN2 3380/4885CHRM1 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.